spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Gardasil 

 HSMN NewsFeed - 11 Oct 2017
SutroVax Appoints Veteran Vaccine Experts to Executive Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Oct 2015
Synthetic Biologics Appoints Raymond Stapleton, PhD, as Senior Vice President, Manufacturing
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Jul 2015
Entasis Appoints Robin David Isaacs as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Jan 2014
Vertex Announces Appointment of Jeffrey A. Chodakewitz, M.D., as Chief Medical Officer and Senior Vice President of Global Medicines Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Mar 2013
Merck Announces Appointment of Roger M. Perlmutter, M.D., Ph.D., As President of Merck Research Laboratories; Peter S. Kim, Ph.D., to Retire
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Jul 2011
Merck Receives Approval to Market GARDASIL(R), ZOLINZA(R) and CUBICIN(R) in Japan
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 22 Dec 2010
US FDA Approves New Indication for Merck's HPV Vaccine, GARDASIL(R)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 18 Mar 2010
Dr. Thomas Hofstaetter Named President and CEO of VaxInnate; Dr. Alan Shaw Assumes New Role as Chief Scientific Officer and Chairman of the Board
Biopharmaceuticals Personnel
 HSMN NewsFeed - 25 Feb 2010
Barry Buckland Joins Ancora Pharmaceuticals Board
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Feb 2010
In Phase III Data Merck's GARDASIL(R) Was Efficacious Against Anal Disease Caused by HPV-6,11,16 and 18
Biopharmaceuticals
 HSMN NewsFeed - 16 Oct 2009
FDA Approves GARDASIL(R) for Use in Boys and Young Men
Biopharmaceuticals FDA
 HSMN NewsFeed - 28 Sep 2009
CSL Biotherapies Reaches Agreement with Merck & Co. on Rights to Market and Distribute Afluria(R) in the U.S.
Biopharmaceuticals Distribution
 HSMN NewsFeed - 9 Mar 2009
Merck and Schering-Plough to Merge
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 9 Jan 2009
Merck & Co., Inc. Receives Complete Response Letter from the Food and Drug Administration for Use of GARDASIL(R) in Women Ages 27 through 45
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 13 Nov 2008
GARDASIL®, Merck's Cervical Cancer Vaccine, Demonstrated Efficacy in Preventing HPV-Related Disease in Males in Phase III Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Jun 2008
Merck & Co., Inc Receives Complete Response Letter from the Food and Drug Administration for Use of GARDASIL(R) in Women Ages 27 through 45
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 19 Mar 2008
Supplemental Application for GARDASIL(R), Merck's Cervical Cancer Vaccine, Designated Priority Review by the U.S. FDA for Use in Women 27 through 45
Biopharmaceuticals
 HSMN NewsFeed - 15 Nov 2007
High-price Vaccines Spark Four-fold Growth in Pediatric & Adolescent Vaccines Market
Biopharmaceuticals
 HSMN NewsFeed - 4 Nov 2007
New Data Presented on GARDASIL(R), Merck's Cervical Cancer Vaccine, in Women Through Age 45
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Sep 2007
Merck to Donate Three Million Doses of Gardasil(R), its Cervical Cancer Vaccine, to Support Vaccination Programs in Lowest Income Nations
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Jul 2007
GSK's Cervical Cancer Candidate Vaccine Cervarix(TM) Receives Positive Opinion in Europe for Prevention of Cervical Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 20 Jun 2007
Merck Provides Update on Status of Supplemental Biologics License Applications (sBLA) for GARDASIL(R)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 17 May 2007
Data Published in The Lancet Show GARDASIL(R) was 100 Percent Effective in Preventing High-Grade Vulvar and Vaginal Lesions Caused by HPV Types 16 and 18
Biopharmaceuticals
 HSMN NewsFeed - 9 May 2007
New England Journal of Medicine Publishes New Data on GARDASIL(R), Merck's Cervical Cancer Vaccine
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Apr 2007
Merck Submits New Cross-Protection Data for GARDASIL(R) to the FDA and Seeks New Indications for Vaginal and Vulvar Cancers
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 22 Mar 2007
CDC Finalizes Advisory Panel Recommendations for GARDASIL(R), Merck's Cervical Cancer Vaccine
Biopharmaceuticals
 HSMN NewsFeed - 18 Jan 2007
GlaxoSmithKline Initiates Head-to-Head Study of Cervical Cancer Vaccines
Biopharmaceuticals
 HSMN NewsFeed - 12 Dec 2006
Merck Remains Confident in Future Growth as it Executes on New Strategy
Biopharmaceuticals
 HSMN NewsFeed - 13 Nov 2006
Merck Launches National Advertising Campaign for GARDASIL(R), Merck's New Cervical Cancer Vaccine
Biopharmaceuticals
 HSMN NewsFeed - 1 Nov 2006
Merck's Cervical Cancer Vaccine, GARDASIL(R), Added to the CDC Vaccines for Children Contract
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Sep 2006
Carrington Subsidiary to Develop Needle-less Delivery of Cervical Cancer Vaccine With the National Cancer Institute (NCI)
Biopharmaceuticals Drug Delivery Oncology
 HSMN NewsFeed - 22 Sep 2006
European Commission Approves GARDASIL(R), Merck's Cervical Cancer Vaccine
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 28 Jul 2006
GARDASIL(R), Merck's Cervical Cancer Vaccine, Receives Positive Opinion from the European Medicines Agency
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 25 Jul 2006
Blue Shield Covers New Vaccine to Prevent Cervical Cancer
Biopharmaceuticals Oncology Reimbursement
 HSMN NewsFeed - 29 Jun 2006
Merck's New Cervical Cancer Vaccine, GARDASIL(R), Unanimously Recommended by CDC Advisory Panel for Vaccination of Girls and Women 11 to 26 Years
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Jun 2006
FDA Approves Merck's GARDASIL(R), the World's First and Only Cervical Cancer Vaccine
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 26 May 2006
Merck to Create New Patient Assistance Program for Vaccines
Biopharmaceuticals
 HSMN NewsFeed - 26 May 2006
FDA Approves ZOSTAVAX(R), Merck's New Vaccine for Prevention of Shingles in Adults Age 60 and Older
Biopharmaceuticals FDA
 HSMN NewsFeed - 18 May 2006
FDA Advisory Committee Votes Unanimously That Clinical Data Support the Efficacy and Safety of GARDASIL(R), Merck's Investigational Cervical Cancer Vaccine
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 7 Feb 2006
GARDASIL(R), Merck's Investigational Cervical Cancer Vaccine, to Receive Priority Review from the U.S. Food and Drug Administration
Biopharmaceuticals FDA
 HSMN NewsFeed - 3 Feb 2006
FDA Approves Merck's ROTATEQ(R), The Only Vaccine in the U.S. to Prevent Rotavirus Gastroenteritis, a Leading Cause of Severe Infant Diarrhea
Biopharmaceuticals FDA
 HSMN NewsFeed - 23 Jan 2006
AVANT Expands Senior Management Team with Appointment of Ronald W. Ellis, Ph.D., Senior Vice President, Research and Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Jan 2006
In a New Study Published in New England Journal of Medicine, ROTATEQ(R), Merck's Investigational Rotavirus Vaccine, Prevented 98 Percent of Severe Rotavirus Gastroenteritis
Biopharmaceuticals Gastroenterology
Return to NewsFeed  

 Additional items found! 4

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 4 additional stories matching:
Gardasil
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.